image: University of Texas at Dallas researchers studied the effects of a ketogenic diet on mice genetically engineered to develop lung cancer that closely mimics human cancer. The mice develop both squamous cell carcinoma (green) and adenocarcinoma (red). Researchers found that in mice fed the keto diet (left), growth of squamous cell lung cancer was suppressed, while adenocarcinoma was unaffected by the diet. Lung tissue from a mouse fed a normal diet is shown at right. view more
Credit: University of Texas at Dallas
It's well known that keeping blood glucose levels in check can help individuals avoid or manage diabetes, but new research led by biologists at The University of Texas at Dallas suggests that restricting blood glucose levels might also keep certain cancers at bay.
In a study published online Aug. 13 in the journal Cell Reports, researchers restricted circulating glucose in mice with lung cancer. Circulating glucose restriction was achieved by feeding the mice a ketogenic diet, which is very low in sugar, and by giving them a diabetes drug that prevents glucose in the blood from being reabsorbed by the kidneys.
"Both the ketogenic diet and the pharmacological restriction of blood glucose by themselves inhibited the further growth of squamous cell carcinoma tumors in mice with lung cancer," said Dr. Jung-Whan "Jay" Kim, corresponding author of the multinational study and an assistant professor of biological sciences at UT Dallas. "While these interventions did not shrink the tumors, they did keep them from progressing, which suggests this type of cancer might be vulnerable to glucose restriction."
While many types of cancer cells are suspected to be heavily dependent on glucose -- or sugar -- as their energy supply, Kim and his colleagues have shown in previous laboratory studies that one specific type -- squamous cell carcinoma -- is remarkably more dependent than other cancer types, such as adenocarcinoma.
"The key finding of our new study in mice is that a ketogenic diet alone does have some tumor-growth inhibitory effect in squamous cell cancer," Kim said. "When we combined this with the diabetes drug and chemotherapy, it was even more effective."
Kim noted that glucose restriction did not have any effect on non-squamous-cell cancer types.
"Our results suggest that this approach is cancer-cell-type specific. We cannot generalize to all types of cancer," he said.
The researchers also examined glucose levels in blood samples from 192 patients who had either lung or esophageal squamous cell cancer, as well as 120 patients with lung adenocarcinoma. The blood samples were taken at random parts of the day and classified into those containing glucose concentrations higher or lower than 120 mg/dL, which is one clinical measure of diabetes. None of the patients had been diagnosed with diabetes.
"Surprisingly, we found a robust correlation between higher blood-glucose concentration and worse survival among patients with squamous cell carcinoma," Kim said. "We found no such correlation among the lung adenocarcinoma patients. This is an important observation that further implicates the potential efficacy of glucose restriction in attenuating squamous-cell cancer growth."
Kim emphasized that more comprehensive and detailed clinical studies are needed, but the results indicate a potentially novel approach to enhancing cancer treatment.
"Manipulating host glucose levels would be a new strategy that is different from just trying to kill cancer cells directly," Kim said. "I believe this is part of a paradigm shift from targeting cancer cells themselves. Immunotherapy is a good example of this, where the human immune system is activated to go after cancer cells.
"Maybe we can manipulate our own biological system a little bit or activate something we already have in place in order to more effectively combat cancer."
###
Lead author of the study was Kim's former graduate student Meng-Hsiung Hsieh MS'18. Other UT Dallas authors included molecular and cell biology graduate students Jashkaran Gadhvi, Haleigh Gerold, Chance Nowak, Hung Do and Simbarashe Mazambani; former research scientist Dr. Yoon Jung Kim, now at UT Southwestern Medical Center's Children's Medical Center Research Institute; undergraduates Marcus Arguez, Jordan Knighton and Matthew Cha; Madison Palmer BS'19; Dr. Zhenyu Xuan, associate professor of biological sciences; Dr. Tae Hoon Kim, head of biological sciences; and Dr. Leonidas Bleris and Dr. Kenneth Hoyt, both associate professors of bioengineering.
Researchers from the University of North Texas and UT Southwestern's Harold C. Simmons Comprehensive Cancer Center and Children's Medical Center Research Institute also participated in the work. Other contributors included researchers at Columbia University, Yale School of Medicine, Carver College of Medicine at the University of Iowa, David Geffen School of Medicine at UCLA, University of Nebraska Medical Center, Kyungpook National University School of Medicine in South Korea and Kyota University Graduate School of Medicine in Japan.
The research was funded by the National Institutes of Health, the Department of Defense, the American Lung Association, the Cancer Prevention and Research Institute of Texas, the American Cancer Society, the Tobacco-Related Disease Research Program, the Japan Agency for Medical Research and Development, and the National Research Foundation of Korea.
Journal
Cell Reports